[Botulinum toxin in XXXX ].

@entity63 @entity158 @entity2701 @entity10 @entity121
Botulinum toxin has meanwhile been approved for a number of indications. It is also gaining acceptance in other indications with a major focus on @entity158 . The most common type of @entity10 is @entity2701 ( @entity2701 ) the pathogenesis of which has not yet been unfolded. As it looks there are vascular, myofascial and supraspinal factors intertwined. It is felt that @entity10 is triggered by myofascial stimuli. The application of botulinum toxin is an intelligent alternative since the favorable effect of pharmacologic and other therapies is limited. Application of BTX should be considered when the pericranial muscles are involved. One of the effects produced lies in the @entity121 , muscular @entity63 and muscle tone. We still don't know whether additional mechanisms such as retrograde uptake and direct antiinflammatory potential are involved. Current data permit the conclusion that headaches are decreased in their frequency and distinctiveness. Significant untoward effects are not to be expected. Neither the ideal dose nor the optimum selection of injection sites have been established as yet, an individual injection scheme is apparently most promising. Injection of the trigger points seems to make sense.
